Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bokemeyer

Showing results (51-60 of 333) with videos related to

Pageof 34
Sort By:
International Journal of Cancer|December 22, 1999
Platinum organ toxicity and possible prevention in patients with testicular cancerJ T Hartmann, C Kollmannsberger, L Kanz, et al.
Onkologie|September 28, 2001
[Treatment of multiple myeloma in elderly patients: consensus of the Geriatric Oncology Working Group of the German Society of Hematologic Oncology and the German Society of Geriatrics]I Genvresse, U Wedding, C Bokemeyer, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell linesW Verbeek, C Bokemeyer, H Falk, et al.
Investigational New Drugs|January 1, 1997
Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenograftsT A Dunn, V Grünwald, C Bokemeyer, et al.
Deutsche Medizinische Wochenschrift (1946)|October 1, 2014
[Current treatment concepts for castration resistant prostate cancer]G von Amsberg, P Stroelin, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2010
Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuationV-F Mautner, R Nguyen, R Knecht, et al.
Andrology|March 30, 2019
Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerationsC Oing, M A Skowron, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2000
Follow up after primary treatment: curable diseases treated non-surgicallyC Bokemeyer, C Kollmannsberger, J T Hartmann, et al.
The Journal of Urology|November 1, 1993
Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult sonC Bokemeyer, M Kuczyk, P Schöffski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Continuing medical education: a must for every medical oncologistD Schrijvers, J B Vermorken, C Bokemeyer, et al.
Pageof 34

Showing results (51-60 of 333) with videos related to

Sort By:
Pageof 34
International Journal of Cancer|December 22, 1999
Platinum organ toxicity and possible prevention in patients with testicular cancerJ T Hartmann, C Kollmannsberger, L Kanz, et al.
Onkologie|September 28, 2001
[Treatment of multiple myeloma in elderly patients: consensus of the Geriatric Oncology Working Group of the German Society of Hematologic Oncology and the German Society of Geriatrics]I Genvresse, U Wedding, C Bokemeyer, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell linesW Verbeek, C Bokemeyer, H Falk, et al.
Investigational New Drugs|January 1, 1997
Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenograftsT A Dunn, V Grünwald, C Bokemeyer, et al.
Deutsche Medizinische Wochenschrift (1946)|October 1, 2014
[Current treatment concepts for castration resistant prostate cancer]G von Amsberg, P Stroelin, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2010
Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuationV-F Mautner, R Nguyen, R Knecht, et al.
Andrology|March 30, 2019
Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerationsC Oing, M A Skowron, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2000
Follow up after primary treatment: curable diseases treated non-surgicallyC Bokemeyer, C Kollmannsberger, J T Hartmann, et al.
The Journal of Urology|November 1, 1993
Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult sonC Bokemeyer, M Kuczyk, P Schöffski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Continuing medical education: a must for every medical oncologistD Schrijvers, J B Vermorken, C Bokemeyer, et al.
Pageof 34